qax567
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01316601)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-13INHIBITOR
IL13 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- qax567
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01316601 | Phase 2 | Jan 1, 2011 | Novartis, University of Zurich |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 1 | 0 | 1 | 2011 |
| University of Zurich | Academic/Hospital | 1 | 1 | 1 | 2011 |
2 organizations
Page 1 / 1